These studies are evaluating a study drug called nadofaragene firadenovec in adults with bladder cancer, called Non-Muscle Invasive Bladder Cancer (NMIBC). Clinical studies like these ones can add to medical knowledge as researchers try to find new and better ways to treat diseases.
Nadofaragene firadenovec is currently approved by the United States FDA under the tradename ADSTILADRIN® for the treatment of high risk NMIBC, that has not responded to Bacillus Calmette-Guérin (BCG) treatment. The use of Nadofaragene firadenovec in this study is investigational.
Bladder cancer studies now enrolling participants:
